These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 4856370)

  • 41. Psychopharmacological effects of thiothixene and related compounds.
    Weissman A
    Psychopharmacologia; 1968; 12(2):142-57. PubMed ID: 4385364
    [No Abstract]   [Full Text] [Related]  

  • 42. Is it possible to predict the clinical effects of neuroleptic drugs (major tranquillizers) from animal data? IV. An improved experimental design for measuring the inhibitory effects of neuroleptic drugs on amphetamine-or apomorphine-induced "Cheroing" and "agitation" in rats.
    Janssen PA; Niemegeers CJ; Schellekens KH; Lenaerts FM
    Arzneimittelforschung; 1967 Jul; 17(7):841-54. PubMed ID: 5632842
    [No Abstract]   [Full Text] [Related]  

  • 43. [Effect of repeated haloperidol and apomorphine administration on the development of tolerance for catalepsy and dopamine receptor hypersensitivity in mice].
    Zharkovskiĭ AM; Matvienko OA; Nurk AM
    Biull Eksp Biol Med; 1984 Oct; 98(10):444-6. PubMed ID: 6541951
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inhibition of circling behavior by neuroleptic drugs in mice with unilateral 6-hydroxydopamine lesions of the striatum.
    Pycock C; Tarsy D; Marsden CD
    Psychopharmacologia; 1975 Dec; 45(2):211-9. PubMed ID: 1240638
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neuroleptic antagonism of dyskinetic phenomena.
    Costall B; Naylor RJ
    Eur J Pharmacol; 1975; 33(2):301-12. PubMed ID: 241654
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Neurotropic properties of fluphenazine].
    Liubimov BI; Raevskiĭ KS; Ostrovskaia RU; Barkov NK; Krolevets GN
    Farmakol Toksikol; 1971; 34(3):287-90. PubMed ID: 5106035
    [No Abstract]   [Full Text] [Related]  

  • 47. Definition and classification of neuroleptics.
    Arnold OH; Collard J; Deniker P; Ginestet D; Hippius H; Itil TM; Labhardt F; Leeds AA; Montanini R; Morozov G; Simon P; Villeneuve A
    Mod Probl Pharmacopsychiatry; 1970; 5():141-7. PubMed ID: 5527163
    [No Abstract]   [Full Text] [Related]  

  • 48. Chemical and pharmacological classification of neuroleptics.
    Janssen PA
    Mod Probl Pharmacopsychiatry; 1970; 5():33-44. PubMed ID: 5535847
    [No Abstract]   [Full Text] [Related]  

  • 49. Cholecystokinin-octapeptide effects on conditioned-avoidance behavior, stereotypy and catalepsy.
    Cohen SL; Knight M; Tamminga CA; Chase TN
    Eur J Pharmacol; 1982 Sep; 83(3-4):213-22. PubMed ID: 6129145
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative studies on flupenthixol and flupenthixol decanoate in amimal and man.
    Jorgensen A; Gottfries CG
    Therapie; 1973; 28(3):459-73. PubMed ID: 4771901
    [No Abstract]   [Full Text] [Related]  

  • 51. Clonidine sensitizes mice for apomorphine-induced stereotypic gnawing: antagonism by neuroleptics and cholecystokinin-like peptides.
    Zetler G
    Eur J Pharmacol; 1985 May; 111(3):309-18. PubMed ID: 2862047
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Effect of neuroleptics, midantan and DOPA on apomorphine sterotypy in rats].
    Kalinin VV
    Farmakol Toksikol; 1977; 40(1):16-9. PubMed ID: 558110
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neuroleptics: relation between cataleptic and anti-turning actions, and role of the cholinergic system.
    Muller P; Seeman P
    J Pharm Pharmacol; 1974 Dec; 26(12):981-4. PubMed ID: 4156868
    [No Abstract]   [Full Text] [Related]  

  • 54. Potentiation of cataleptogenic effects of neuroleptics by prostaglandins.
    Herman ZS; Słomińska-Zurek J; Kryk A; Kmieciak-Kołada K
    Pol J Pharmacol Pharm; 1978; 30(5):639-46. PubMed ID: 35782
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enhanced effect of haloperidol and apomorphine after hypophysectomy: pharmacokinetic considerations.
    Lloyd KG; Bianchetti G; Worms P; Morselli PL
    J Pharm Pharmacol; 1983 Mar; 35(3):166-9. PubMed ID: 6132974
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effects of neuroleptics and nialamide on defensive conditoned reflex in rats.
    Plech S; Drybański A; Herman Z
    Acta Physiol Pol; 1975; 26(3):255-60. PubMed ID: 1180066
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Phenamine antagonism as a treat for experimental evaluation of neuroleptics].
    Raevskiĭ KS
    Farmakol Toksikol; 1973; 36(2):149-54. PubMed ID: 4151668
    [No Abstract]   [Full Text] [Related]  

  • 58. Preclinical evaluation of AHR-2244 a new psychotherapeutic agent.
    Johnson DN; Funderburk WH; Ward JW
    Arch Int Pharmacodyn Ther; 1974 Oct; 211(2):326-40. PubMed ID: 4477709
    [No Abstract]   [Full Text] [Related]  

  • 59. Behavioral, anti-dopaminergic, and prohypnotic effects of neuroleptics during and after prolonged treatment.
    Biazzi A; Fregnan GB
    Adv Biochem Psychopharmacol; 1980; 24():351-7. PubMed ID: 6105785
    [No Abstract]   [Full Text] [Related]  

  • 60. Pharmacological properties of new neuroleptic compounds.
    Coscia L; Causa P; Giuliani E; Nunziata A
    Arzneimittelforschung; 1975 Sep; 25(9):1436-42. PubMed ID: 25
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.